Lexicon Licenses Gene Target Technology to Immunex | GenomeWeb

NEW YORK, Feb 6 – Lexicon said Tuesday it has licensed its gene targeting technology to Immunex, bringing to 14 the number of its sublicensees.

Under the terms of the deal, Lexicon will receive annual license fees, technology usage frees for any model Immunex develops using the technology, as well as milestone payments for future discoveries.

Exact figures were not disclosed.

Lexicon of The Woodlands, Tex., determines gene function using large-scale knockout mouse technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.